Compare PFX & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFX | CYPH |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.7M | 73.3M |
| IPO Year | 2010 | 2019 |
| Metric | PFX | CYPH |
|---|---|---|
| Price | $44.59 | $2.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.1K | ★ 14.2M |
| Earning Date | 08-05-2026 | 11-11-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | ★ 103.87 |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | ★ $1,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $408.92 |
| P/E Ratio | $148.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.30 | $0.49 |
| 52 Week High | $56.48 | $4.19 |
| Indicator | PFX | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 48.96 |
| Support Level | $44.01 | $0.68 |
| Resistance Level | $45.03 | $3.23 |
| Average True Range (ATR) | 0.74 | 0.38 |
| MACD | -0.05 | -0.15 |
| Stochastic Oscillator | 17.36 | 13.11 |
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.